I am a medical writernd will assist you in translating the provided Chinese content into English, ensuring accuracy and professionalism:
Epidemiology and Unmet Needs in Advanced Breast Cancer
Breast cancer is the most frequently diagnosed cancer among women globally and is one of the leading causes of cancer-related deaths in women [1]. In 2022, new cases of breast cancer in women in China accounted for approximately 15% of all new female cancer cases, making it the most common malignant tumor among Chinese women [2]. Among these cases, HR+/HER2- and triple-negative breast cancer (TNBC) account for about 85% [3].
Despite significant improvements in the prognosis of patients with advanced HR+/HER2- and TNBC due to the development of PD-1/PD-L1 inhibitors, CDK4/6 inhibitors, PARP inhibitors, and endocrine therapies, some patients still have suboptimal responses. Therefore, there remains a need for effective and safe therapeutic agents to further improve the outcomes of patients with advanced HR+/HER2- and TNBC.
